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1. Introduction 
The association between HLA-B27 and ankylosing spondylitis (AS) has lead to intense 
research over the last 4 decades. In the course of this research, it was possible to obtain the 
best example of an association between a disease and a genetic marker. Genetic factors 
contribute with more than 90% for the susceptibility risk to AS being the MHC region, in  
particularly HLA-B27, the main contributor (Brown, et al., 1996). This evidence is supported 
by studies using familial cohorts; segregation and twin studies (Brown, et al., 1997; Jarvinen, 
1995; Rubin, et al., 1994). 
The advent of genotyping technologies, in particular the use of genome-wide linkage studies 
(GWLS) and whole-genome association studies (WGAS), allowed a wider view of the genetic 
factors related to AS and supported the presence of non-MHC genetic AS susceptibility 
factors. The first whole genome wide linkage study identified numerous  loci in linkage with 
the disease, on chromosomes 1p, 2q, 6p, 9q, 10q, 16q, and 19q (Laval, et al., 2001). These results 
prompted to an even more intense research on AS and, consequently, the investigation of 
other areas outside MHC. Later, three other major studies tried to narrow down the 
chromosome areas first identified (Consortium TASC, 2010; Consortium TASC/WTCCC2, 
2011; Consortium WTCCC/TASC, 2007). This way it was possible to identify specific gene 
regions that would lead to new insights in the mechanisms underlying the disease 
susceptibility (Table 1). In this chapter we intend to provide an overview of the main genes, 
other than HLA-B*27, which were identified as been associated to AS during the last decade. 
2. Genes with consistent association to ankylosing spondylitis 
2.1 Major histocompatibility complex 
At this moment, over 80 subtypes of HLA-B27 (coding and non-coding) are known 
(http://hla.alleles.org/alleles/class1.html). All variants were originated from the parental 
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B*27:05 as a result of different mechanisms, such as point mutation, gene conversion, 
reciprocal recombination and interlocus gene conversion (Reveille, J D & Maganti, 2009). 
The data obtained from studies within same ethnic groups allowed the perception that there 
are differences in the rank of association of each B27 subtype and AS. The allele HLA-
B*27:05 is the most frequent variant of B27 worldwide, although the frequencies of all the 
known subtypes diverge when different ethnic groups are compared (Reveille, J D, 2011). 
For that reason, it has been very difficult to establish a clear ranking of B27 variants and 
association with AS, that could be applied to all groups (Brown, 2010). 
Among European Caucasians, B*27:05 and B*27:02 are suggested to be the strongest disease 
associated variants (Brown, et al., 1996; MacLean, et al., 1993; Reveille, J D, 2011). In Asian 
cohorts, HLA-B*27:04 was found to be more strongly associated with AS than B*27:05 (Hou, 
et al., 2007; Liu, et al., 2010; Lopez-Larrea, C, et al., 1995). Other B*27 alleles were already 
reported in AS cases, namely B*27:01 (Ball & Khan, 2001), *27:03 (Gonzalez-Roces, et al., 
1997), *27:07, *27:08 (Armas, et al., 1999), *27:10 (Garcia, et al., 1998), *27:14, *27:15 (Garcia-
Fernandez, et al., 2001), and *27:19 (Tamouza, et al., 2001). 
The information obtained in studies with B27 subtypes confirm this allele as a critical factor 
on AS susceptibility. However, since it is known that less than 8% of B27 individuals 
develop AS (van der Linden, et al., 1984), it is difficult to exclude another gene nearby B27 as 
the one responsible for the AS susceptibility.  The high level of linkage disequilibrium (LD) 
in the MHC region is a major barrier to the identification of any other possible gene directly 
involved. 
New insights were reached inside MHC, despite all the complexity involving this region. 
HLA-B60 (B*40:01) was identified as the first non-HLA-B*27 gene strongly associated to AS 
susceptibility. The first report of this association stated that HLA-B60 was increased among 
AS patients HLA-B27 positive, in five independent data sets. On the other hand, the studied 
variant was not increased in HLA-B27 negative patients with AS. A whole view of the 
obtained data show that the susceptibility to AS is threefold higher in individuals both 
B27/B60 positive (Robinson, et al., 1989). These findings were later supported by other 
studies using different cohorts. In a group of UK patients with AS, not only the association 
strength of B27/B60 positive was confirmed. The presence of HLA-B60 was observed in 
HLA-B27 negative patients, suggesting that, despite having a much weaker effect, it may 
function as an AS susceptibility gene independent of HLA-B27 (Brown, et al., 1996). 
Moreover, in a group of Taiwan Chinese it was confirmed the association of B60 with AS 
and also, for the first time, an independent association of B61 was found. Both alleles were 
strongly increased in HLA-B27 negative patients (Wei, et al., 2004). Although all this 
replications confirming the relationship between HLA-B60 and AS, the same was not seen in 
Mexican Mestizos where, instead, HLA-B49 was identified as significantly increased in 
patients with AS (Vargas-Alarcón, et al., 1994). 
Another allele, HLA-B*39, has been reported to be increased in HLA-B27 negative White 
Caucasian and Japanese AS patients (Khan, et al., 1980; Yamaguchi, et al., 1995). The studies 
that provided this data used small cohorts and consequently it is not possible to state if this 
is an effective association neither the level of its power. Even so, it was formulated a 
parallelism between B27 and B*39 components of the peptide-anchoring B pocket as well as 
peptide-ligand motifs, supporting some potential explanation for the HLA-B27 influence in 
the development of AS (Yamaguchi, et al., 1995). This results were not confirmed in a cohort 
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composed by White Caucasians and Mexican Mestizos (Maksymowych, W P, et al., 2000). 
The prevalence of AS in Sub-Saharan black Africans is very low, a fact that has been related 
to the low frequency of HLA-B27 in that region. The allele HLA-B*1403, found exclusively in 
African or Afro-American populations, was reported in four out of eight AS Togolese 
patients, a population where HLA-B27 is considered to be virtually absent (Lopez-Larrea, C, 
et al., 2002). It was the first time that a variant of B*14 was found to be present in AS 
patients. However, a confirmation is needed and a mandatory replication of this study in 
other sub-Saharan populations is still missing. These findings in HLA-B alleles, other than 
HLA-B27, are not clear enough to understand if there is a direct association with AS or if 
this is the result of LD with another MHC gene. 
Data derived from GWAS for susceptibility loci in AS extended the HLA association in the 
MHC region between markers D6S276 and DRB1 (Brown, et al., 1998b). This finding has 
been supported by the results obtained in different ethnic groups (Brown, et al., 1998a; 
Jaakkola, et al., 2006; Kchir, et al., 2010; Mahfoudh, et al., 2011; Ploski, et al., 1995; Said-
Nahal, et al., 2002; Sims, A M, et al., 2007). HLA-DRB1 was found to have a strong 
association with AS. In British patients the level of this association was increased in DR1 
homozygotes, a fact that may suggest a B27-independent association, excluding a possible 
LD effect (Brown, et al., 1998a; Sims, A M, et al., 2007). On the other hand, in French families 
the association between DR1 and AS seems to be a consequence of LD with HLA-B27 (Said-
Nahal, et al., 2002). Here, it was reported an excess of transmission of HLA-DR4 to patients, 
independently of its LD with B27. Together with the lack of transmission of DR4 to HLA-
B27 positive siblings, this report suggests that the presence of DR4 may contribute to AS 
simultaneously with B27. The HLA-DR1 is associated to SpA in Mexican patients, however, 
this finding was not confirmed when only AS patients were analysed (Vargas-Alarcon, et 
al., 2002). The sample size and the high prevalence of peripheral enthesopathy and 
arthropathy in the studied group may explain this result, different from the results obtained 
in the British population. 
Consistent results, on the association of DRB1 alleles with AS, have been difficult to 
ascertain in different ethnic groups. A Finnish report proposed that, in this specific 
population, the HLA-DRB1 alleles do not seem to play a strong role in AS susceptibility , but 
may influence the age of symptom onset (Jaakkola, et al., 2006). The results, in this case-
control study, are limited due to the sample size. Still, a strong association of DRB1*08, both 
independent and as part of a HLA-B27 haplotype, was suggested. HLA-DRB1*08 had been 
already reported in juvenile-AS B27-positive individuals, in Norwegian population (Ploski, 
et al., 1995). Two haplotypes were identified in a British case-control study: B*27positive 
/DRB1*07positive and B*27negative /DRB1*03positive (Sims, A M, et al., 2007). The 
frequency of HLA-DRB1*15 was found to be increased, in Tunisian AS patients, but this 
allele was in LD with B27 (Mahfoudh, et al., 2011). Within the same population, a case-
control study reported a significant increase in HLA-DRB1*11 frequency among patients. It 
was also found a possible protective effect of HLA-DRB1*13 (Kchir, et al., 2010).  
Recently, in a Spanish/Portuguese cohort, it was reported the association between HLA-
DPA1 and HLA-DPB1 alleles and AS (Díaz-Peña, et al., 2011). The study was focused on 
these two MHC genes that lay on a region unrelated to B27. Both AS patients and controls 
were HLA-B27 positive. This way it was possible to achieve results from an HLA-B27 
neutral point of view. The data showed significant results between AS and DPA1*01:03, 
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DPA1*02:01, DPB1*13:01. It was also found an association between two haplotypes and AS, 
namely: DPA1*02:01-DPB1*11:01:01 and DPA1*02:01-DPB1*13:01. This was the first study to 
show an association between this region of MHC and susceptibility to AS. Consequently, 
further replicates are needed to confirm these results. 
 
Genes with consistent association to ankylosing spondylitis 
Gene Locus Mechanism Population origin 
HLA-B27 6p21.3 
Presents endogenously processed antigens 
to T cells 
Caucasian and non-
Caucasian 
HLA-B60 
(*4001) 
6p21.3 
Presents endogenously processed antigens 
to T cells 
Caucasian and non-
Caucasian 
ERAP1/ART
S1 
5q15 
Peptide trimming prior to HLA Class I 
presentation and cleaving cytokine 
receptors from cell surface 
Caucasian and Han-
Chinese 
IL23R 1p31.3 
Differentiation of naive CD4 T cells into 
helper Th17 T cells 
Caucasian and Han-
Chinese 
KIF21B 1p32 
Transport of essential cellular components 
along axonal and dendritic microtubules Caucasian 
- 2p15 Unknown Caucasian 
- 21q22 Unknown Caucasian 
Genes with suggestive association to ankylosing spondylitis 
Gene Locus Mechanism Population origin 
IL1R2 2q11 Interference in the binding of IL-1 to IL-1R1 
Caucasian and non-
Caucasian 
IL12B 5q31 
Heterodimerises with the IL23 p19 subunit, 
to form IL23R 
Caucasian 
CYP2D6 
22q13.
1 
Metabolism of xenobiotics 
Caucasian (North 
European) 
TNFR1 12p13 Influence on TNF signaling Caucasian 
TNFSF15 9q32 
Differentiation of naive CD4 T cells into 
helper Th17 T cells 
Caucasian 
ANTRX2 4q21 
Binds to collagen IV and laminin, possibly 
involved in extracellular matrix adhesion 
Caucasian and Han-
Chinese 
Other genes 
Gene Locus Mechanism Population origin 
ANKH 5p15.2 
Exports inorganic pyrophosphate from 
intracellular to extracellular compartments. 
Regulates tissue calcification 
Caucasian and Japanese 
(small cohorts) 
KIR 
19q13.
4 
Regulates activation of NK cells via 
recognition of HLA class I molecules on 
target cells 
Caucasian and Han-
Chinese (small cohorts) 
TGFB1 19q13 
Mediates inflammation, fibrosis and bone 
remodelling 
Caucasian (one study) 
TNAP 1p36.1 
Receptor on monocytes important in 
apoptosis, binds lipopolysaccharide 
Caucasian (one study) 
CD14 5q31.1 
A phosphoethanolamine and pyridoxal-5’-
PO4 actingectophosphatase. Degrades PPi 
Caucasian (Finnish small 
cohort) 
Table 1. Genes associated to AS - adapted from (Brown, 2010; Reveille, J D, 2011). 
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2.2 Non-major histocompatibility complex genes 
2.2.1 ERAP1/ARTS1 
The association between Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) and AS was 
first reported in Caucasians, together with IL23R (Consortium WTCCC/TASC, 2007). 
Contrarily to the IL23R, the association of ERAP1 was later confirmed in other ethnic groups 
(Chen, R., et al., 2011). ERAP1 molecules are encoded by the oxytocinase subfamily, a group 
of three genes located on the chromosome 5  (5q15) (Brionez & Reveille, 2008), and are 
located in the endoplasmatic reticulum lumen (Saric, et al., 2002). 
The involvement between ERAP1 and MHC class I presentation was the first suggested and 
confirmed function attributed to this aminopeptidase (Saric, et al., 2002; Saveanu, et al., 
2005). ERAP1 is MHC class I dependent and play a major role on peptide trimming, 
processing it to optimal length, for presentation at cell surface (Saveanu, et al., 2005), having 
an important connection to the immune recognition mechanism related to CD8+ T cells. 
However, it is proposed that the referred importance varies depending both on the antigen 
and the cell physiological state. It was shown that, contrarily to other peptidases, ERAP1 
cleaves NH2-terminal from peptides longer than ten residues and, consequently, is able to 
produce peptides containing eight to nine residues from longer precursors (York, et al., 
2002). This fact support the relation with MHC class I molecules and indicates a possible co-
evolution between these 2 groups of molecules, since MHC class I require eight to nine 
residues peptides for a stable binding (York, et al., 2002). Due to the involvement between 
ERAP1 and MHC class I, these molecules and their trimming mechanisms are consequently 
involved with HLA-B27, an MHC class I variant (Campbell, et al., 2011).  For some years, it 
was stated that a deeper understanding about ERAP1 function and its relation with B27, at 
peptide production level, would lead to new insights on the paths that support the well 
known association between HLA-B27 and AS.. This aspiration was recently fulfilled by the 
latest GWAS on AS (Consortium TASC/WTCCC2, 2011). It was shown that HLA-B27 
positive and negative AS cases differ in association with ERAP1. This fact provided the first 
reliable replicated example of a gene-gene interaction in AS, indicating that the mechanism 
by which HLA-B27 induces AS involves aberrant presentation or handling of peptides 
(Consortium TASC/WTCCC2, 2011). 
The cleavage of cytokine cell surface receptors is another function documented to ERAP1. 
The shedding of IL-1R2, promoted by ERAP1, was already reported in co-
immunoprecipitation experiments (Cui, et al., 2003a). Through the use of cell lines, it was 
possible to achieve a correspondence between ERAP1 overexpression, the increase of IL1-R2 
shedding and the decrease of membrane–associated IL1-R2. It was also found that ERAP1 is 
necessary for constitutive IL1-R2 shedding, as basal IL1-R2 shedding is absent from ERAP1 
knockout cell lines (Cui, et al., 2003a). The exact same correlations were already observed in 
reports regarding TNFR1 (Cui, et al., 2002) and IL6R (Cui, et al., 2003b). These findings were 
not confirmed when was measured the appearance of those receptors in cell culture 
supernatants from single-cell suspensions, stimulated with plate-bound anti-CD3 (Clone 
145-2C11) and phorbol 12-myristate 13-acetate (PMA), prepared from mouse spleens. No 
difference in the levels of these receptors was observed over time, indicating that ERAP1 
does not have a major influence on cytokine receptor trimming, at least in mice (Consortium 
TASC/WTCCC2, 2011). Further tests may contribute to the clarification of the mechanisms 
underlying the association between ERAP1 and AS. An abnormal increase or decrease in the 
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amount of those cytokine cell surface receptors is an expected outcome of ERAP1 
malfunctioning. Thus, the susceptibility to AS can emerge as a consequence of pro-
inflammatory effects related to that amount variation (Chen, R., et al., 2011; Consortium 
WTCCC/TASC, 2007). 
Since the confirmed association between ERAP1 and AS reported in 2007(Consortium 
WTCCC/TASC, 2007), some replications occurred in studies involving Caucasian 
(Consortium TASC, 2010; Harvey, et al., 2009a; Maksymowych, W. P., et al., 2009; Pazar, et 
al., 2010; Pimentel-Santos, et al., 2009; Tsui, F. W., et al., 2010) and Han Chinese cohorts 
(Bang, et al., 2011; Choi, et al., 2010; Davidson, et al., 2009). The Wellcome Trust Case-
Control consortium and Australo-Anglo-American Spondyloarthritis Consortium first 
described the association of five ERAP1 single nucleotide polymorphisms (SNPs) and AS 
(Consortium WTCCC/TASC, 2007), namely rs27044, rs17482078, rs10050860, rs30187 and 
rs2287987. Two of these SNPs, rs27044 and rs30187, gathered more consistent results in the 
subsequent reports and were the only markers that showed significant association both in 
Caucasian and in Han Chinese groups (Choi, et al., 2010; Harvey, et al., 2009a; 
Maksymowych, W. P., et al., 2009; Pazar, et al., 2010; Pimentel-Santos, et al., 2009). The 
significant relation between rs27044 and AS was not confirmed in Canadian, contrarily to all 
other replicates involving this SNP and Caucasian groups. However, in that same cohort, it 
was found an ERAP1 haplotype, containing rs27044, which increased the risk of AS: 
rs2044/10060860/30187-CCT (Maksymowych, W. P., et al., 2009). The other mentioned SNP, 
rs30187, did not show a significant association with AS in a group from Hungary (Pazar, et 
al., 2010). However, this result has low impact compared to the other studies performed, 
since the obtained P-value was 0.051 and the sample was the smallest of all the mentioned 
cohorts. The rs30187 (Arg528Lys) is the only coding marker within a SNP block recently 
identified in GWAS (Consortium TASC, 2010). This variant showed a really strong 
significant association in another GWAS using a large Caucasian cohort (P=1.8x10-27) 
(Consortium TASC/WTCCC2, 2011). It was shown that this marker originates a significant 
decrease in aminopeptidase activity toward a synthetic peptide substrate. Moreover, 
modeling of ERAP1 protein points out to the presence of Arg528 at the mouth of the 
putative enzyme substrate pocket. This location can explain the reduction of the 
aminopeptidase activity of the molecules that contain this variation (Goto, et al., 2008; 
Kochan, et al., 2011). These results and reported data from family based studies (Tsui, F. W., 
et al., 2010) support this SNP as one of the ERAP1 variants with strongest association to AS. 
The remaining SNPs found by The Australo-Anglo-American Spondyloarthritis Consortium 
(TASC) & Wellcome Trust Case Control Consortium (WTCCC) didn’t show consistent 
results in other sudies. The first published study, after WTCCC/TASC report, was not able 
to identify a significant association between rs2287987, rs17482078 or rs10050860 and AS in a 
Portuguese group (Pimentel-Santos, et al., 2009). The same result was obtained in a Han 
Chinese group (Choi, et al., 2010). The rs17482078 significant association (Consortium 
WTCCC/TASC, 2007) was not confirmed also in already mentioned Hungary group (Pazar, 
et al., 2010). Other replications using Caucasian cohorts were able to find significant 
associations between rs2287987, rs10050860 and AS (Harvey, et al., 2009a; Maksymowych, 
W. P., et al., 2009; Pazar, et al., 2010). Recently, a meta-analysis that included all the ERAP1 
association studies, confirmed the presence of a significant association between the SNPs 
reported by the Consortium WTCCC/TASC and AS (Chen, R., et al., 2011). Moreover, it was 
proposed that the contradictory results, obtained in some replications, can be an effect of  
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the clinical heterogeneity, ethnic differences or real genetic heterogeneity, the small sample 
size of the studies or their low statistical power (Chen, R., et al., 2011). 
The Consortium TASC included ERAP1 in the first GWAS for AS, already mentioned above. 
This work included a large Caucasian cohort and narrowed down the ERAP1 region, 
associated to AS, to a block of SNPs lying in a 4.6-kb region between rs27529 (exon 9) and 
rs469758 (intron 12) (Consortium TASC, 2010). The identified region showed an association 
50 times more significant than any other imputed SNP (P<10-11). The overall results showed 
strong association of two SNPs that were not reported in previous Caucasian studies, 
rs27037 and rs27434. The data obtained in a Han Chinese group, published before TASC 
GWAS showed moderate association of rs27037 (P=0.012) and did not observe the 
association of rs27434 (P=0.14) (Davidson, et al., 2009). The same result was attained by the 
recent meta-analysis already cited (Chen, R., et al., 2011). On the other hand, the strong 
association of both markers was recently confirmed in a Korean group (Bang, et al., 2011). 
Once more, together with ethnic differences, the results seem to be influenced by the effect 
genetic heterogeneity. 
The data concerning ERAP1 haplotypes is limited; however the available results seem to 
point out to some haplotypes that influence the risk of disease. The rs2044/10060860/30187-
CCT haplotypes increased the risk of disease in 3 Canadian case-control cohorts. This 
haplotype is in one of the two strongly significant haplotypes, out of four, that were 
identified among Koreans: rs27044/rs17482078/rs10050860/rs30187-GCCT and rs27044/ 
rs17482078/rs10050860/rs30187-CCCC (Choi, et al., 2010). All these four SNPs formed an 
LD block with almost complete LD (95<D’<100) (Choi, et al., 2010; Tsui, F. W., et al., 2010). 
The Canadian study reported a protection effect of rs30187/26618/26653-CTG ERAP1 
haplotype (Maksymowych, W. P., et al., 2009). A family-based study was not able to support 
the significant association of rs2044/10060860/30187 haplotype, but here a relatively small 
sample was used (Tsui, F. W., et al., 2010). Moreover, the results are probably an 
underestimate since some of the studied families had more than two affected individuals (3–
5) and the method used by the authors for power estimation took into account only two 
affected family members. Despite this lack of confirmation, it was possible to identify 
significant association between rs27044/rs2549782-GT and rs30187/rs2549782-TT 
haplotypes and AS. In addition, a novel finding showing that rs27044/rs30187/rs2549782-
GTT haplotype in the ERAP1-ERAP2 loci was significantly associated with disease 
susceptibility for both models used (Tsui, F. W., et al., 2010). 
2.2.2 IL23R 
The association between Interleukin 23 receptor (IL23R) and AS has been confirmed 
throughout the last few years, since the first association evidence, reported by the 
WTCCC/TASC study (Consortium WTCCC/TASC, 2007) . 
IL23R is a member of heamopoietin receptor family, which binds to IL-23 mediating its 
activity. This hemopoietic cytokine receptor is encoded on chromosome 1 (1p31.3), by a gene 
located 150kb far from the gene for IL-12Rǃ2 (Parham, C., et al., 2002). IL23 is a 
heterodimeric cytokine consisting of two subunits: p40, which is shared with IL-12, and p19 
(Oppmann, et al., 2000). IL-23 has also other biological connections with IL-12; activated 
human PHA blast T cells, when induced by IL-23, register a better proliferation and IFN-Ǆ 
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production, like when they are induced by IL-12. However, IFN-Ǆ levels produced in cells 
stimulated by IL-23 are always lower than those induced by IL-12. In the presence of IL-23, 
naive T cells only increase the producing of IFN-Ǆ after a long stimulation. In contrast, 
memory T cells - human and mouse – and NKL cells register a strong response to IL-23, 
enhancing IFN-Ǆ production (Oppmann, et al., 2000; Parham, C., et al., 2002). The cells 
response to either IL-12 or IL-23 is linked to the level of IL-12Rǃ2 or IL23R expression, 
respectively (Parham, C., et al., 2002). 
IL23R is one of the two subunits of IL-23 receptor complex, present on IL-23-responsive 
cells. The other component is IL-12Rǃ1 and is shared with IL-12 receptor. Despite the 
similarities in the structure of both receptors, in the presence of IL23R subunit, cells respond 
to IL-23 and not to IL-12 (Parham, C., et al., 2002). Human  IL23R is expressed on T cells, 
Natural-Killer (NK) cells, monocytes and DCs, all cells that are able to respond to IL-23 
(Belladonna, et al., 2002; Parham, C., et al., 2002). The IL23R has an important role in CD4 T-
cell differentiation, since it encodes a critical cytokine receptor in the TH17 lymphocyte 
subset. The TH17 cells were already identified as mediators of inflammatory process in 
several models of autoimmunity (Cua, et al., 2003; Murphy, et al., 2003). Furthermore, they 
are considered as a distinct subset of T-cells, expressing high levels of IL-17 in response to 
stimulation (Park, et al., 2005) and are associated to tissue damage in brain, joints, heart, 
lungs and intestines (Steinman, 2007). Genetic variants of  IL23R have also been related with 
susceptibility to several autoimmune diseases, namely inflammatory bowel disease (IBD) 
(Duerr, et al., 2006), psoriasis (Cargill, et al., 2007), multiple sclerosis (Nunez, et al., 2008) 
and AS (Consortium WTCCC/TASC, 2007). A significant association between IL-12Rβ1 and 
AS (rs6556416; P=1.9x10-8), which encodes one of IL23R and IL-12R subunits, was reported 
recently by the Consortium WTCCC2/TASC (Consortium TASC/WTCCC2, 2011). 
The Consortium WTCCC/TASC reported the strong association (p ≤ 0.008) of eight  IL23R 
SNPs and AS, rs11209026, rs1004819, rs10489629, rs11465804, rs1343151, rs10889677, 
rs11209032, rs1495965 (Consortium WTCCC/TASC, 2007). The strongest association 
reported was with SNP rs11209032 (p= 7.5 × 10-9) with an attributable risk of 9%. The power 
of this association was consistent, even when only AS cases, without IBD. were considered. 
It was stated that this fact could be the result of a primary association with AS, and thus, not 
related to the presence of IBD (Consortium WTCCC/TASC, 2007). These findings were 
replicated in several studies; however, there are some conflicting results, especially when 
analyzing different ethnic groups. A recent GWAS used the same British cohort, and 
included a new sample composed by Australian, British and North American individuals. In 
this large cohort a strong AS association to SNP rs11209026 (p= 2.3 × 10-9) was identified 
(Consortium TASC, 2010). This association was soon after confirmed by the most recent 
GWAS reported by the TASC/WTCCC2 consortia  (Consortium TASC/WTCCC2, 2011).  
Closely after the WTCCC/TASC report, a Canadian and a Spanish study were able to 
replicate some of the already studied IL23R SNPs (Rahman, et al., 2008; Rueda, et al., 2008). 
The Canadian study encompassed 3 cohorts and tested the association of 10 IL23R SNPs: 
rs7517847 and rs2201841, plus the SNPs reported by WTCCC/TASC. Significant 
associations, to the SNPs rs1004819 and rs11209032, were also found in a Portuguese cohort 
(Pimentel-Santos, et al., 2009), and in the Alberta population, respectively. The SNPs 
rs11209026 (Arg381Gln) and rs11465804 revealed association with AS in both 
Newfoundland and Toronto groups. The last SNP, revealed the strongest protective effect in 
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these two cohorts and it was in LD with rs11209026. The Toronto population also registered 
significant differences in rs7517847 (Rahman, et al., 2008).  
In the Spanish group, the obtained results were able to corroborate the previous findings for 
rs1343151, rs11209026 and rs10889677. In this cohort the SNPs revealed a protective effect. 
The association of the remaining SNPs, reported by the consortium WTCCC/TASC, was not 
confirmed. The involvement of rs11465804 was not tested, on the other hand, like in the 
Canadian study, it was included the SNP rs7517847 but no significant result was found for 
this variation (Rueda, et al., 2008). In this population, rs1343151 showed a stronger 
association (P=2x10-4). This findings, together with the Canadian study results previously 
mentioned (Rahman, et al., 2008), points out to a protection effect of the Arg381Gln non-
synonymous polymorphism. The changing of Arg381 for Gln381 may modify the interaction 
between IL23R and its associated JAK2 kinase (Parham, C., et al., 2002). The authors 
proposed that this variation can interfere with the  IL23R transducing pathway leading to a 
reduction in cellular response to IL-23, explaining this way the protective effect of Gln381 
allele (Rahman, et al., 2008; Rueda, et al., 2008). 
A Portuguese study was not able to confirm all this findings (Pimentel-Santos, et al., 2009). 
The modest power of the study can explain the results. However, as it was already 
mentioned, a significant association was found for rs1004819. The minor allele frequencies 
observed in this study were similar to those reported in British and North Americans. 
Furthermore, this association had a similar magnitude of effect to the one already reported 
in those populations. The attributable risk for rs1004819 in Portuguese cohort, is very similar 
to the one reported to rs11209032 in the British/North American populations (Consortium 
WTCCC/TASC, 2007; Pimentel-Santos, et al., 2009). Using the obtained results, the authors 
performed a meta-analysis study combining the Portuguese data and the previously 
published Spanish data (Rueda, et al., 2008). Considering fixed effects, three IL23R SNPs 
revealed significant association rs1004819, rs1343151 and rs11209026. When random effects 
were considered for the analysis of combined data, only rs1004819 was found to have 
significant association, confirming the result found when only the Portuguese cohort was 
analyzed (Pimentel-Santos, et al., 2009). 
The results obtained for rs1004819 in the Iberian population were confirmed in the 
Hungarian population (Pimentel-Santos, et al., 2009; Safrany, et al., 2009). This study was 
performed with a small number of samples; even so, it was possible to register some 
significant associations. It was shown that the presence of rs1004819 allele A increases the 
risk for AS in more than two-fold. The same increase was registered when rs10889677 was 
considered. Significant results were also found for rs11209026. Besides the SNPs reported in 
the initial association study (Consortium WTCCC/TASC, 2007), the authors also included 
rs11805303, which was significantly increased in patients with AS. The minor allele of this 
SNP conferred a 1.6-fold risk for the development of the disease in the studied cohort 
(Safrany, et al., 2009). The presence of rs11209026 revealed no significant difference between 
patients and controls when only HLA-B27 positive AS patients were included in the 
statistical analysis. Thus, the association found for rs11805303 and rs10889677 had a 
marginal significance when comparing controls with the HLA-B27 patients. Nevertheless, 
all the other variants kept their significant results, showing that HLA-B27 status has no real 
effect on the effect of  IL23R (Safrany, et al., 2009). 
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A meta-analysis, reported at the same year, included the first United Kingdom and United 
States cohort published (Consortium WTCCC/TASC, 2007), the Canadian groups (Alberta, 
Newfoundland and Toronto) (Rahman, et al., 2008), the Spanish results (Rueda, et al., 2008) 
plus a new British group (Karaderi, et al., 2009). Just like stated by WTCCC/TASC, the 
results of this study confirmed the association between AS and all the eight IL23R SPNs 
analyzed. Once more, the strongest associations were seen with rs11209026 (P<10-10) and 
rs11209032 (P=4.06x10-9) (Karaderi, et al., 2009). The last variant had the same order of 
magnitude reported by the WTCCC/TASC study (Consortium WTCCC/TASC, 2007). This 
meta-analysis confirmed the connection of IL23R and AS susceptibility in Caucasians. 
The first replication, performed in a group with a different ethnic background, did not 
confirm the association of IL23R and AS in Han Chinese (Davidson, et al., 2009; Sung, et al., 
2009). These findings may indicate a difference in the mechanism of disease pathogenesis 
between Caucasian and Han Chinese populations. The authors proposed that the 
development of AS developing Chinese can result from a mechanism independent of any 
IL23R polymorphism. This difference could be the result of the association with a different 
gene also involved in the IL23R signaling pathway (Davidson, et al., 2009). Other 
explanation to this lack of association is the absence of polymorphism of rs11209026 in 
Chinese. This variant, as described above, is pointed out as one of the causative SNP for 
disease susceptibility in Europeans. However, recent published data reported association of 
some IL23R SNPs and AS in a Chinese cohort (Wang, et al., 2010). In this group it was 
found, for the first time, a significant association between rs6677188, located in the 
intergenic region, and AS susceptibility. The previously reported association of rs11209032 
in Caucasians was confirmed also in Chinese. Through the analysis of paiwised LD, it was 
found that rs11209032 and rs6677188 were in strong LD, in this population (Wang, et al., 
2010). 
2.2.3 KIF21B 
The gene KIF21B (Kinesin Family 21B) is one of the most recent loci with confirmed 
association to AS. This gene belongs to a family of kinesin motor proteins that are involved 
in the transport of essential components along axonal and denditric microtubules by 
neurons. A GWS found strong association for rs11584383 (1q32) (P = 1.6x10-10), a SNP 
located downstream of and flanked by KIF21B (Danoy, et al., 2010). This strong association 
was corroborated by WTCCC2/TASC. Here, the SNP rs2297909 showed the strongest 
association with AS (P=5.2 × 10−12) (Consortium TASC/WTCCC2, 2011). Both studies were 
conducted with Caucasian cohorts. Despite the confirmed association in this ethnic group, 
further replications in other ethnic groups are mandatory. 
2.3 Intergenic regions - 2p15 and 21q22 
It has been estimated that approximately 25% of the human genome consists of gene deserts 
defined as generally long regions, ranging from a few base pairs to 5.1 Mb, containing no 
protein-coding sequences and with no obvious biological functions (Venter, et al., 2001). 
Ovcharenko et al. found that conservation clearly separates two distinct categories of gene 
deserts: weakly conserved variable gene deserts and more conserved stable gene deserts 
(Ovcharenko, et al., 2005). Moreover, it has already been shown that some human gene 
deserts harbour distant regulatory elements that are deeply conserved in vertebrate species 
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(Kimura-Yoshida, et al., 2004; Nobrega, et al., 2003). Several diseases have been associated 
with these particular areas of the genome; possible explanations to elucidate the 
mechanisms underlying these associations include: 1) epigenetic effects, 2) unknown 
protein-coding transcripts, 3) effects of long range transcriptional regulatory elements and 4) 
effects of non-coding RNA that can influence gene expression (Brown, 2010). 
A GWAS has recently identified the new association of two narrow intergenic regions, in 
chromosomes 2 (23kb) and 21 (11kb), with AS. This study found, in each intergenic region, a 
block of SNPs in tight linkage disequilibrium encompassing areas that likely contain the 
causative variants responsible for the observed association (Consortium TASC, 2010). 
Another GWAS recent study replicated this association and has shown that SNPs at these 
intergenic regions are independent of the HLA-B27 presence, since it is associated with AS 
in both HLA-B27 positive and HLA-B27-negative patients (Consortium TASC/WTCCC2, 
2011).  
The intergenic area 2p15 does not contain any known gene and, until now, this has been the 
only association to a disease (Reveille, J. D., et al., 2010). The association to AS was already 
been replicated in a small study in the Spanish population. The SNP rs10865331 was typed 
in four hundred and fifty six AS patients and 300 healthy donors, and the result was a 
significant association with AS, while no association was found for rs2242944, in 21q22 
(Consortium TASC/WTCCC2, 2011). 
The other intergenic AS associated area, at chromosome 21q22, has already been associated 
with a closely related condition: paediatric-onset inflammatory bowel disease (IBD) 
(Kugathasan, et al., 2008). Remarkably, the most strongly IBD associated SNP is in strong 
linkage disequilibrium with the strongest ankylosing spondylitis-associated marker 
(Consortium TASC, 2010). The nearest gene, to this region, lies at 82kb distance (PSMG1) 
and encodes for a proteasome assembly chaperone 1 (Consortium TASC, 2010). According 
to the authors’ opinion, it is unlikely that PSMG1 is a candidate gene directly involved in AS 
susceptibility since 1) this gene was not differentially expressed in peripheral blood 
mononuclear cells from cases with active AS when compared with healthy controls, 2) the 
large distance to the associated locus and 3) the lack of evidence of a relevant biological 
function.  
It is suggested that both these regions at chromosomes 2p15 and 21q22, contain long 
mRNA-like noncoding RNA species or until now unreported protein-coding genes that may 
be involved in AS susceptibility (Consortium TASC, 2010). 
3. Genes suggestively associated with ankylosing spondylitis 
3.1 IL1 gene cluster 
Interleukin-1 (IL-1) and its related family members are key cytokines in autoimmune and 
inflammatory diseases produced by monocytes, macrophages, and dendritic cells. They are 
cell surface associated proteins and stimulate the expression of several genes, affecting both 
the innate and acquired immune systems (Dinarello, 2002).  IL1-F1, IL1-F2, IL1-F3, and IL1-
F4 are the primary members of the family. IL1-F1, IL1-F2, and IL1-F4 are each agonist while 
IL1-F3 is a receptor antagonist for IL1-F1, IL1-F2 (Dinarello, 2002).  When the antagonist 
occupies the receptor, there is no signal transduction as the IL1-F1 and IL1-F2 can not bind 
www.intechopen.com
 
Clinical and Molecular Advances in Ankylosing Spondylitis 
 
114 
the specific receptor. All IL-1 genes are located on the long arm of chromosome 2 except IL-
18 and IL-18 binding protein (IL-18BP) which are located on chromosome 11. Some member 
of the family as IL1-F5, IL1-F7, and IL1-F9 are gene duplications and they are very closely 
related to IL1-F3 (Mulero, et al., 1999). The exact function of these genes is still unclear.  
The IL-1 receptor family is composed of nine genes. IL1-R1, IL1-R2, and IL1-R3 are the bona 
fide receptors while the rest are called ‘orphan’ receptors as they lack of specific ligand 
Anyway, some gene regulation studies found non-specific proteins binding to orphan 
receptors (Gayle, et al., 1996; Moritz, et al., 1998; Parnet, et al., 1996; Torigoe, et al., 1997). 
The most studied receptor of the family is the IL1-R2 (Symons, et al., 1991). IL1-R2 receptor 
acts as a decoy receptor. It has a high affinity for IL1-F1 and IL1-F2 and a lower affinity for 
IL1-F3. After the cleavage from cell membrane by ERAP1, IL1-R2 binds IL1-F1 interfering 
with IL1-F1 / IL1-R1 binding. Its extracellular domain is homologue of the IL1-R1 but the 
intracellular domain is shorter and lacks of TIR domain (Dunne & O'Neill, 2003). Therefore 
when activated, IL-R2 is unable to initiate any biological response.  
Positive association between AS and IL1-F3 gene was observed in earlier studies with high 
frequency of the allele 2 of IL1-F3 variable nucleotide tandem repeat (VNTR) in AS patients 
(Dunne & O'Neill, 2003; van der Paardt, et al., 2002). The result was further confirmed 
through a recent study on meta-analysis of IL-1 gene cluster (Wu & Gu, 2007). A significant 
association between two IL1-F3 intronic SNPs and AS susceptibility was also found at 
position 30735 and 30017 in exon 6 (Chou, et al., 2006; Maksymowych, W. P., et al., 2003). A 
significant difference of the distribution of haplotypes was found between the AS affected 
and healthy individuals. On the contrary, in earlier studies no association between AS and 
IL1-F3 gene was found (Djouadi, et al., 2001; Jin, et al., 2004; Kim, et al., 2005; 
Maksymowych, W. P., et al., 2006; Timms, A. E., et al., 2004). These findings were also 
observed in the genome scan carried out by North American Spondylitis Consortium 
(NASC) (Jin, et al., 2004). In this work, six exons and introns in 102 white patients and 50 
controls were sequenced and no association was revealed. Moreover, other genes in the IL-1 
cluster have been analyzed. In nine IL-1 genes, were identified SNPs showing significant 
association with AS (Timms, A. E., et al., 2004). Maksymowych et al. identified 14 SNPs with 
high association in at least one cohort (Maksymowych, W. P., et al., 2006). The most 
significant cohorts were in IL1-F1 and IL1-F2. In a more recent meta-analysis nine SNPs 
were analyzed and a strong association was observed in three IL1-F1 loci (Sims, A. M., et al., 
2008).    
3.2 ANTXR2 
The ANTXR2 gene encodes for a transmembrane protein which serves as receptor of anthrax 
toxin (Thomas & Brown, 2010). Also known as capillary morphogenesis protein 2 (CMP2), 
the receptor recognises and binds the toxin, allowing anthrax to attach the cells and 
triggering the disease process.  It is widely expressed in human tissue including in the 
hearth, lung, liver, placenta, small intestine, kidney, colon, and skeletal muscles. Expressed 
primarily in macrofages, it is involved in capillary formation and extracellular matrix 
adhesion (Reveille, J D, 2011). Recessive mutations in ANTXR2 gene are associated to two 
autosomal diseases, infantile systemic hyalinosis (ISH; MIM#237490) and juvenile hyaline 
fibromatosis (JHF; MIM#228600) (Consortium TASC, 2010).  
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In a recent study on unrelated cases of AS among Australian, British, and North American 
individuals of European descent, carried out by TASC, a strong association between 
polymorphism in ANTXR2 gene and AS was found (Consortium TASC, 2010).  In the same 
year, investigating on AS susceptibility in 1164 Korean patients, Bang et al. confirmed the 
differentially expression of ANTXR2 gene in AS (Bang, et al., 2011). In contrast no 
association was observed between ANTXR2 polymorphism and AS in Chinese Han 
population (Chen, C., et al., 2010).  With these divergent results, it is still not clear if 
ANTXR2 influences the disease and how it is involved in the pathogenesis. IT has been 
suggested that it can act at intestinal permeability level given its function in epithelial 
barriers (Thomas & Brown, 2010). The previous results reported by TASC were confirmed 
by another GWS that also found significant association in the ANTXR2 area (P = 9.4 × 10−8) 
(Consortium TASC/WTCCC2, 2011). 
3.3 TNFSF15 
The Tumor Necrosis Factor Ligand Superfamily, Member 15 (TNFSF15, also known as TNF 
superfamily ligand A, TL1A or vascular endothelial cell growth inhibitor, VEGI) is a TNF-
like factor encoded on the chromosome 9 (9q32). The molecules are primarily expressed in 
endothelial cells and its expression is highly inducible by TNF and IL-1A (Migone, et al., 
2002; Yue, et al., 1999). Strong evidences point to a significant genetic association between 
the TNFSF15 gene and inflammatory bowel disease (IBD). The data was obtained in 
populations from different ethnic backgrounds, namely Caucasians and Japanese 
(Yamazaki, et al., 2005). A WGAS for AS in Caucasians reported the existence of linkage on 
chromosome 9q (Laval, et al., 2001). This was supported by another WGS for 
spondyloarthropathies (SpA) susceptibility genes, performed on multiplex families, which 
detected a significant linkage on chromosome 9q31-34, including the TNFSF15 encoding 
region (Miceli-Richard, et al., 2004). However, this region was not identified in a recent 
GWAS (Consortium TASC, 2010). 
Recently, comprehensive linkage and association analyses reported, for the first time, an 
association between several SNPs near the TNFSF15 gene and SpA (Zinovieva, et al., 2009). 
The authors aimed to narrow down the susceptibility region for SpA found on the first 
GWAS reported by the same authors (Miceli-Richard, et al., 2004). The obtained data 
showed two areas of statistically significance linkage. The highest linkage peak was located 
on the marker D9S1824 at 115.9 Mb from the p-telomere. The second significant area was 
located near D9S1682, a suggestive linkage peak reported in WGS for AS (Laval, et al., 2001). 
This finding supports the validity of linkage between this region and SpA. 
The analysis of combined data from family-based and case/control studies showed a strong 
association (P<0.001) of 7 SNPs: rs4979459, rs7849556, rs10817669, rs10759734, rs6478105, 
rs10982396 and rs10733612 (Zinovieva, et al., 2009). The SNP rs4246905 also showed a 
significant result but with a lower level (P=0.01). Six of this SNPs compose a 40.3 Kb block 
with a high degree of LD, found in the same study. This LD block included two genes, 
LOC389786 and TNFSF15 (Zinovieva, et al., 2009). The rs6478105 revealed to be the strongest 
individual associated SNP in the overall dataset (P=3x10-5). The SNPs associated with 
Crohn’s disease were not associated with SpA in this study. Haplotypes research also 
confirmed this tendency and showed that haplotypes composed of markers of this block 
were significantly associated with the disease. Two significant individual haplotypes were 
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found in family-based study: rs7849556/ rs10817669/ rs10759734/ rs6478105/ rs10982396/ 
rs10733612 - AAAACC and rs7849556/ rs10817669/ rs10759734/ rs6478105/ rs10982396/ 
rs10733612 - CGGACT. The pooled case/control investigation revealed a significant strong 
association of the individual haplotype rs7849556/ rs10817669/ rs10759734/ rs6478105/ 
rs10982396/ rs10733612 - CGGGGT (Zinovieva, et al., 2009).  
TNFSF15 is a ligand for the receptors DR3 (death domain receptor 3, also known as 
TNFRSF25 (tumor necrosis factor receptor super-family, member 25) and TR6/DcR3 (decoy 
receptor 3, also called TNFRSF6B - tumor necrosis factor receptor super-family, member 6b) 
(Migone, et al., 2002). The ligand-receptor pairing of TNFSF15-DR3 was already pointed as a 
regulator of Th17 differentiation and activation (Pappu, et al., 2008; Takedatsu, et al., 2008). 
An increased level of Th17 cells in AS patients, when compared to healthy controls, was 
already reported (Jandus, et al., 2008). Therefore, targeting the TNFSF15-DR3 pathway could 
provide new insights in the role of TNFS15 in AS development. 
3.4 TNFRSF1A and TRADD 
The TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A, also known as 
tumor necrosis factor receptor 1 - TNFR1) association with AS was reported by the TASC 
GWAS. Several TNFRSF1A SNPs showed moderate levels of association in the discovery set 
and, among them, rs1800693 showed the strongest association (P=6.9x10-5) (Consortium 
TASC, 2010). It was hypothasized that TNF1, encoded by TNFRSF1A, was cleaved by 
ERAP1. The data suggested that ERAP1 extracellular domain binds to the TNFR1 
extracellular domain and acts as an extracellular TNFR1 regulatory protein that would 
promote TNFR1 shedding (Cui, et al., 2002). However, as already mentioned in ERAP1 
section, no correlation between presence of ERAP1 and decrease of TNFR1 levels was 
observed in cultured cells from mice (Consortium TASC/WTCCC2, 2011). 
TNF antagonists are highly effective in suppressing inflammation in AS. Thus, some data 
obtained from studies with mice showed that mesenchymal cells are common primary 
targets for TNF in the development of AS, and that selective expression of TNFRSF1A on 
those cells is enough to cause the complete development of AS, as well as inflammatory 
polyarthritis and inflammatory bowel disease (IBD) (Armaka, et al., 2008). The 
determination of the polymorphisms involved on that action would allow a better 
understanding of the relation between TNFRSF1A gene and AS. TRADD (TNF receptor type 
1-associated death domain) is located on chromosome 16q, a region already reported in 
linkage studies (Laval, et al., 2001). TRADD registered moderate levels of association and 
lies between the SNPs rs9033 and rs868213, which already showed strong association with 
AS (Pointon, et al., 2010). This gene is a key component of the TNFR1-signaling cascade and 
is involved in TLR3, TLR4 and D3 signaling (Chen, N. J., et al., 2008; Chinnaiyan, et al., 1996; 
Hsu, H., et al., 1995).  
Recently it was found an AS associated SNP at chromosome 12p13 between LTBR 
(lymphotoxin beta receptor) and TNFRSF1A (rs11616188; P = 4.1 × 10−12). The authors also 
found an association at chromosome 17q21 near TBKBP1 (encoding TBK binding protein 1), 
a component of the TNFR signaling pathway (rs8070463, P = 5.3 × 10−8). Here, TRADD also 
showed suggestive association with AS in this study, namely SNP rs9033 (P = 4.9 × 10−5) 
(Consortium TASC/WTCCC2, 2011). Once more, it is mandatory to continue research at this 
level to determine the precise mechanism underlying these associations. 
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3.5 CYP2D6 
The cytochrome P450 enzymes are responsible for the majority of oxidative (phase I) drug 
metabolism (1)(Gonzalez, 1992); they are polymorphic although 5-10% of Europeans lack 
this activity (described as poor metabolisers) (Cholerton, et al., 1992). At least 15 allelic 
variants of CYP2D6, that is inherited as an autosomal recessive trait, can cause poor 
metaboliser phenotype, but 75% of these are CYP2D6*4 (Brown, et al., 2000). The CYP2D6 
genotype was found to be associated with other chronic inflammatory disease and with 
cancer (Baer, et al., 1986; Daly, et al., 1994). 
Beyeler et al. (Beyeler, et al., 1996) first reported a relationship between this gene and the 
susceptibility to AS, investigating 54 patients and 662 healthy volunteers. The association 
was modest between AS and CYP2D6 genotype and the effect was greatest for the CYP2D6B 
allele.  
Brown et al. (Brown, et al., 2000) studied linkage of the CYP2D6 gene and association of the 
main poor metabolizer genotype in 617 unrelated AS patients,  402 healthy controls, and in 
361 families with AS. Significant association was observed between homozygosity for 
CYP2D6*4 and AS, but heterozygosity for allele 4 was not disease associated, and weak 
linkage of the CYP2D6 polymorphism and AS was found with a LOD score of 0.9. The 
authors suggested that dysfunction of the CYP2D6 gene increases the risk of AS, although 
only contributing a small proportion of the overall risk of the disease.  
A more recent Turkish study, investigating 100 unrelated AS patients and 52 healthy 
controls, found no significant risk of AS development for patients with one or two 
CYP2D6*4 alleles (Erden, et al., 2009).  
In conclusion, the cytochrome P450 gene debrisoquine 4-hydroxilase (CYP2D6), encoded at 
22q13.1, may have a moderate support for involvement in susceptibility to AS. The 
mechanisms for susceptibility are unknown but it is possible that the ubiquitous 
environmental trigger of AS is a natural toxin and reducing its metabolism could increase 
susceptibility to disease (Brown, 2006). 
4. Other genes 
4.1 KIR 
The Killer immunoglobulin-like receptor  (KIR) genes are a polymorphic group of genes 
located on chromosome 19q13.4, and they span 150Kb of the leucocyte receptor complex 
(LCR) (Hsu, K. C., et al., 2002).  They express a family of proteins which are activating and 
inhibitory receptors expressed on natural killer (NK) cells and on a subset of T cells (CD8+).  
They have been classified in two types: Activating KIRs (KIR2DS and KIR3DS), which have 
a short (S) cytoplasmic tail with the capacity to interact with activating adaptor proteins 
such as DAP12 (Lanier, et al., 1998), and inhibitory KIR (KIR2DL and KIR3DL), which has 
one or two immunoreceptor tyrosine-based inhibition motifs in their long (L) cytoplasmic 
tail. Further to the allelic polymorphism, haplotypic variability is also described and 
according to gene content, haplotypes were divided in two basic groups: Haplotype A 
contains only one activating KIR gene, 2DS4, whereas Haplotype B contains various 
combinations of activating KIR genes, KIR2DS1, -2DS2, -2DS3, -2DS5, - 3DS1, and -2DS4, 
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exhibiting extreme diversity, resulting in different signaling potentials to NK and T cells 
(Hsu, K. C., et al., 2002). 
The precise function of some KIRs is controversial but it was demonstrated that mature class 
I complexes act as ligands for immunomodulatary receptors, and it is known that KIR 
proteins recognize subsets of HLA-A, -B, or –C alleles (Parham, P., 2005).  It is possible that 
KIRs may synergise with HLAs to generate activating or inhibitory compound genotypes 
that provide different levels of activation and inhibition for NK or T cells, which may be 
associated with differing susceptibility to or protection against a range of diseases.   
A study in Caucasian populations demonstrated genetic evidence for the implication of 
KIR3DL1 and the activating counterpart, KIR3DS1 in AS (Lopez-Larrea, C., et al., 2006). In 
this study the inhibitory allele was decreased in AS patients compared with B27-positive 
healthy controls, whereas KIR3DS1 was increased in AS patients. Another study by the 
same group in two Asian B27-positive populations (China and Thailand), reported some 
KIR associations with AS susceptibility (Diaz-Pena, et al., 2008). The authors hypothesized 
that AS patients could possess more activating KIR genes than the healthy control subjects, 
which could create a genetic imbalance between inhibitory and activating KIR genes that 
could have influence on the AS pathogenesis. 
Another study genotyped 200 UK AS patients and 405 healthy controls for 14 KIR genes. 
Additionally, sequence-specific oligonucleotide probes were used to subtype 368 cases with 
AS and 366 controls for 12 KIR3DL2 alleles. The authors concluded that neither the KIR gene 
content of particular KIR haplotypes nor KIR3DL2 polymorphisms contribute to AS 
(Harvey, et al., 2009b). 
Two more recent studies, one from China and another one from Spain investigated the 
association of KIR and AS susceptibility. The Chinese study investigated 115 unrelated 
HLA-B27-positive AS patients and 119 HLA-B27-positive healthy controls, and concluded 
that the frequencies of KIR2DL1 and KIR2DL5 were significantly higher in the AS patient 
group although they did not reach statistical significance. Furthermore, the investigators 
also concluded that HLA-Cw*08 was present more frequently in AS patients than in 
healthy B27 controls, raising the possibility that HLA-Cw*08 recognized KIRs through the 
Asp80, thereby contributing to the immune regulation in AS (Jiao, et al., 2010). In the 
Spanish study 270 AS patients and 435 healthy HLA-B27-positive controls from Spain 
were genotyped for KIR3DL1/S1 alleles. The authors found that the KIR3DS1*013 allele 
frequency was increased in patients with AS, and that the null allele KIR3DL1*004 was a 
unique inhibitory KIR3DL1 allele that showed a negative association with AS (Diaz-Pena, 
et al., 2010). 
Genome-wide scans have implicated regions on chromosomes 2q, 6q, 10q, 11q, 16q, 17q, 
and 19q in AS. The KIR genes are located on chromosome 19q13.4 in the LCR, and 
obviously are good candidates for AS susceptibility (Carter, et al., 2007). More recent 
investigations using different approaches like the report of the TASC/WTCCC2, did not 
identify this chromosome region as involved in AS susceptibility (Consortium 
TASC/WTCCC2, 2011). The influence of KIR/HLA genotypes in AS susceptibility may be 
mediated by a general imbalance between the protective/inhibitory and the 
risk/activating allotypes. Further studies in other populations are needed to confirm the 
role of KIR genes in AS susceptibility. 
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4.2 ANKH 
The ANKH gene maps to human chromosome 5 (5p15.1) and encodes a 492 amino acid 
multiple-pass transmembrane protein (ANK) which transports the inorganic pyrophosphate 
(PPi) across the plasma membrane into the extracellular compartment (Gurley, K.A., et al., 
2006b). ANK function is essential in joints to inhibit mineral formation in joints and 
maintain mobility (Gurley, K. A., et al., 2006a). Mutations in the ANKH gene have been 
consistently associated with two autosomal dominant skeletal disorders: familial 
chondrocalcinosis (MIM #118600) and craniometaphyseal dysplasia (MIM #123000). 
In the last decade, a very small number of reports suggested an association of ANKH with 
AS. In 2003, two polymorphisms - ANKH-OR and ANKH-TR - in complete linkage 
disequilibrium, located in the 5’-noncoding region and in the promoter region of this gene, 
respectively, were found to be significantly associated with AS. After linkage analysis and 
family-based association studies the authors concluded that ANKH could be among the 
most important non-MHC loci for AS susceptibility (Tsui, F W, et al., 2003). In a follow-up 
study, with 201 multiplex AS families, it was reported that the region associated with AS in 
women only showed significance in the test of interaction among the subset of families with 
affected individuals of both genders. These findings supported the concept that ANKH plays 
a role in genetic susceptibility to AS revealing a gender-genotype specificity in this 
interaction (Tsui, H W, et al., 2005). Contradicting these results, a small study performed in a 
cohort of 233 patients and 478 controls, revealed no association between ANKH locus and 
either susceptibility to AS or its clinical manifestations (Timms, A E, et al., 2003). 
In another study, the authors examined a total of 45 SNPs in 15 genes by a sequential 
screening. 170 Japanese AS patients and 896 controls for the SNPs were first genotyped.  
Then, eight SNPs with P < 0.05 in the first screen were genotyped for 108 additional 
Japanese patients. The replication of the association of the most significant SNP was checked 
by genotyping 219 Taiwanese AS patients and 185 controls. After combining the first and 
second screens, four SNPs showed nominal significance of P < 0.05. One synonymous SNP 
in ANKH, c.963T > G, showed a marginal association in the Japanese population (P = 0.045) 
(Furuichi, et al., 2008). This association is not consistent and was not replicated in recent 
GWAS studies with large cohorts. 
4.3 TGFB1 
The TGFB1 gene codifies for the human transforming growth factor ǃ1 (TGFǃ1) (van der 
Paardt, et al., 2005b) located on chromosome 19q21.1. It is a multifunctional cytokine 
involved in inflammation, fibrosis and bone remodelling (Reveille, J D, 2011). The 
concentration of TGFǃ1 in cartilage and bone is 100 times superior to other tissues 
(Centrella, et al., 1991). It was demonstrate that injections of TGFǃ1 into young rat bone 
induce formation of cartilaginous mass and subsequently bone tissue (Joyce, et al., 1990). 
Whether the effect is positive with growing bones or negative with damaged bones depends 
on the concentration of TGFǃ1 and the presence of other hormones (Archer & Keat, 1999). 
Therefore, TGFǃ1 represent a good candidate for a key cytokine in a disease characterized 
by chronic inflammation of the sacroiliac joints. 
A marginal association between TGFB1 and AS was observed in a study of Finnish and 
British families (Jaakkola, et al., 2004) and in a Scottish case study (McGarry, et al., 2002). 
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The Scottish genotype showed a strong correlation with high concentration of TGFǃ1. On 
the other side, no significant association with AS susceptibility was reported in two 
following studies in Dutch and Southern Chinese populations (Howe, et al., 2005; van der 
Paardt, et al., 2005b);  although, in the Dutch study, the frequency of mutated allele was 
greater in AS patients than in the healthy individuals. The TGFB1 polymorphism might be 
implicated to the AS disease at bone formation level but further studies are necessary. 
Understanding the role of TGFǃ1 in AS could be interesting especially to develop new 
pharmacological approaches in order to prevent the disorder (van der Paardt, et al., 
2005b). 
4.4 CD14 
The Cluster of differentiation 14 (CD14) gene maps to chromosome 5 (5q22-q3215q31.1) and 
encodes 2 protein forms: a 50 to 55 kD glycosylphosphatidylinositol-anchored membrane 
protein (mCD14) and a monocyte or liver-derived soluble serum protein (sCD14) that lacks 
the anchor. Both molecules are essential for lipopolysaccharide (LPS)-dependent signal 
transduction. Increased sCD14 levels are associated with inflammatory infectious diseases 
and high mortality in gram-negative shock (LeVan, et al., 2001). 
A putative role of CD14 in the pathogenesis of AS was investigated due to its significant 
role on the innate immune system. The polymorphism C-260T was studied in genomic 
DNA from 113 unrelated Dutch AS patients and 170 healthy controls. No significant 
differences were found between the frequency of this allele in patients and controls 
suggesting that this polymorphism is not involved in the susceptibility to AS (van der 
Paardt, et al., 2005a). On the other hand, evidence of association was identified between 
this allele and AS in a small cohort of Finnish families (Pointon, et al., 2008). No other 
studies about CD14 and its association with AS have been published suggesting that this 
association is not established. 
4.5 TNAP 
Tissue-Nonspecific Alkaline Phosphatase (TNAP) is an isozyme of a family of four 
homologous human alkaline phosphatase genes. It is present in the matrix vesicles and has 
the ability of hydrolyze PPi. In humans, this enzyme is enconded by the gene TNAP, that 
maps in chromosome 1, containing 12 exons.  Deactivating mutations in the TNAP gene 
cause hypophosphatasia [MIM#241500 (Infantile form), MIM#146300 (Adult type)], 
characterized by poorly mineralized cartilage and bones, spontaneous bone fractures, 
chondrocalcinosis by calcium pyrophosphate deposition and elevated concentrations of 
pyrophosphate (PPi) (Mornet, et al., 1998). 
One study has shown the significant association of the TNAP haplotype rs3767155(G) / 
rs3738099 (G) / rs1780329 (T)  with AS but in men only (Tsui, H. W., et al., 2007). This 
association was later investigated in a case control study involving a cohort of 353 AS 
patients and 514 unrelated healthy controls, and a family-based association study with 57 
pedigrees, of the Chinese Han population. Two intronic SNPs (rs3767155 and rs1780329) 
were genotyped; the results showed no significant difference in allele, genotype or 
haplotype frequencies between AS patients and controls (Cheng, et al., 2009). No other 
studies have replicated the association of TNAP to AS. 
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5. Conclusion 
AS susceptibility is no longer an HLA-B27 exclusive. The association of AS and ERAP1, 
IL23R and the intergenic regions 2p15 and 21q22 has been confirmed in large cohort studies. 
This knowledge increased the complexity of genes involved in AS susceptibility; however, it 
is shortening the way to a better understanding about AS immunopathogenesis. 
The identification of associated genetic regions outside MHC will require a large number of 
replicates in populations with different ethnic backgrounds. The consistent data already 
obtained, and the results that will come up from new replicates, should provide a solid basis 
to new research that may unravel the mechanisms underlying all these associations. 
Consequently, the AS pathway will start to present an even more conclusive and consistent 
shape, providing new tools to clinicians and allowing an improvement in the disease 
diagnosis and treatment. More, the identified and confirmed markers could be used to 
create a complete diagnosis testing panel, along with HLA-B27. 
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